DEA Reschedules CBD-Based Drug to Schedule V
According to a report from CNBC.com (1), the U.S. Drug Enforcement Administration (DEA) has rescheduled GW Pharmaceuticals’ cannabidiol (CBD)-based drug, Epidiolex, to schedule V.
According to a report from CNBC.com (1), the U.S. Drug Enforcement Administration (DEA) has rescheduled GW Pharmaceuticals’ cannabidiol (CBD)-based drug, Epidiolex, to schedule V.
The U.S. Food and Drug Administration (FDA) approved Epidiolex in June 2018, as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy-Lennox-Gastaut syndrome and Dravet syndrome-in patients two years of age and older (2,3). The FDA’s approval of Epidiolex forced the DEA to consider how to classify it since cannabis is considered a schedule I drug, which is defined as having no currently accepted medical use and a high potential for abuse. Epidiolex will be classified as a schedule V controlled substance, which is the lowest level, defined as those with a proven medical use and low potential for abuse.
According to the CNBC report, the rescheduling applies to CBD containing no more than 0.1% tetrahydrocannabinol (THC), in FDA-approved drug products. This allows GW Pharmaceuticals to sell Epidiolex, but it does not broadly apply to all CBD products.
For more information on the descheduling, please read the full report from CNBC (1).
References:
- https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html
- https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm?utm_campaign=06252018_PR_FDA%20approves%20marijuana-derived%20drug%20to%20treat%20two%20forms%20of%20epilepsy&utm_medium=email&utm_source=Eloqua
- http://www.cannabissciencetech.com/news/fda-approves-first-drug-containing-cbd
Ep 27: Tracking Strains in Diverse Landscapes
July 2nd 2025In this latest installment of Noid Knowledge, we are joined by Daniela Vergara, PhD, Hemp Specialist at the Cornell Cooperative Extension, and Anna Schwabe, PhD, Associate Lecture Professor at the University of Colorado, discussing the evolution of cannabis cultivation and the need for regional climate data. Their recent project, funded by the Agricultural Genomics Foundation, studies 10 cannabis varieties grown by farmers in different regions, specifically plant characteristics, soil type, and harvest metrics. They aim to understand how environmental factors affect cannabis yield and quality, providing actionable insights for farmers and breeders.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.
Best of the Week: June 27 – July 03, 2025
July 4th 2025Here, we bring you our top five recent articles covering cannabis on state-tribal cannabis regulations in Montana, our podcast discussion on cannabis cultivation, our blog on compliance with federal regulations, public commentary on new standards, and hemp packaging enforcement in Florida.
